TherapeuticsMD Inc (TXMD)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $20.95M
Last updated: Nov 17, 2026 at 4:10 PM ET
TherapeuticsMD Inc (TXMD) Statistics
TherapeuticsMD (TXMD) has a market cap of $20.95M and an enterprise value of $10.50M. It holds $10.45M more cash than debt, 49.87% of its market cap. Revenue grew 33.94% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 49.87% below the market cap, as cash exceeds debt.
| Market Cap | $20.95M |
|---|---|
| Enterprise Value | $10.50M |
| Latest price (Nov 17, 2026) | $1.91 |
Key Dates
The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 29, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 13, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 5.9x and 0.8x. Its year-end P/S ranged from 1.3x to 74.2x from 2016 to 2025.
| P/S Ratio | 5.9x |
|---|---|
| P/B Ratio | 0.8x |
| P/TBV Ratio | 0.9x |
| P/OCF Ratio | 6.2x |
Enterprise Valuation
Counting debt and cash, the company is valued at 6.3x EBITDA.
| EV / Earnings | 86.1x |
|---|---|
| EV / Sales | 2.8x |
| EV / EBITDA | 6.3x |
| EV / EBIT | 13.8x |
Price Statistics
The stock is down 2.55% over 52 weeks and trades 2.55% below its 50-day average.
| Beta (1Y) | 0.28 |
|---|---|
| 52-Week Change | -2.55% |
| 1-Month Change | +2.69% |
| 3-Month Change | -5.91% |
| 6-Month Change | -6.37% |
| 5-Year Change | -95.05% |
| 10-Year Change | -99.37% |
| Total Return (1Y) | -2.55% |
| Total Return (3Y CAGR) | -5.59% |
| Total Return (5Y CAGR) | -42.06% |
| Return vs SPY (1Y) | +12.47% |
| Max Drawdown (1Y) | -38.99% |
| Max Drawdown (3Y) | -75.58% |
| Sharpe Ratio (1Y) | 0.35 |
| Correlation with SPY (1Y) | 0.06 |
| 50-Day Average | $1.96 |
| 200-Day Average | $2.08 |
| 52-Week Range | $1.43 to $2.95 |
| RSI (14 Days) | 54.5 |
| Average Volume (20 Days) | 17.84K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.32x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 3.32x |
|---|---|
| Quick Ratio | 3.32x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is 0.44% and return on assets is 0.32% over the last 12 months.
| Return on Equity (ROE) | 0.44% |
|---|---|
| Return on Assets (ROA) | 0.32% |
| Return on Capital Employed (ROCE) | 2.33% |
| ROA (5Y Average) | -1.76% |
| ROIC (5Y Average) | -2.34% |
| Asset Turnover | 0.10x |
Taxes
Income tax took 17.02% of pretax income over the last 12 months.
| Income Tax (TTM) | $32.00K |
|---|---|
| Effective Tax Rate | 17.02% |
Scores
TXMD has an Altman Z-Score of -33.29, in the distress zone below 1.81, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -33.29 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $3.75M over the last 12 months.
| Revenue | $3.75M |
|---|---|
| Revenue Growth (YoY) | +33.94% |
| Gross Profit | $3.75M |
| Operating Income | -$3.98M |
| Pretax Income | $188.00K |
| Net Income | $122.00K |
| EBITDA | $1.85M |
| EBIT | $762.00K |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 72.82% of the $37.93M in total assets.
| Cash and Equivalents | $10.45M |
|---|---|
| Total Debt | $0 |
| Net Cash | $10.45M |
| Net Cash Per Share | $0.90 |
| Working Capital | $12.17M |
| Shareholder Equity | $27.62M |
| Book Value Per Share | $2.39 |
| Tangible Book Value | $24.16M |
| Tangible Book Per Share | $2.09 |
| Total Assets | $37.93M |
| Total Liabilities | $10.31M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | $3.37M |
|---|---|
| FCF Per Share | $0.29 |
| Depreciation and Amortization | $1.09M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -106.28%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -106.28% |
| Pretax Margin | 5.02% |
| Net Margin | 3.26% |
| EBITDA Margin | 49.37% |
| EBIT Margin | 20.35% |
| Gross Margin (5Y Average) | 88.70% |
Growth
Revenue fell 64.91% a year over 3 years, and EPS 81.74% a year.
| Revenue Growth (3Y CAGR) | -64.91% |
|---|---|
| Revenue Growth (5Y CAGR) | -45.84% |
| EPS Growth (3Y CAGR) | -81.74% |
| FCF Growth (3Y CAGR) | -35.16% |
| Book Value Per Share Growth (2Y CAGR) | -4.36% |
| Tangible Book Per Share Growth (2Y CAGR) | -0.32% |
Stock Splits
The last split was a 1-for-50 reverse split on May 9, 2022.
| Last Split Date | May 9, 2022 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:50 |
Peer Position
Against 6 similar companies, TXMD has the highest P/S.
P/S RatioPeer median 1.6x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -7.46%
| P/S Ratio | 5.9x vs 1.6x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +33.94% vs -7.46% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About TXMD
What is TXMD's market cap?
TherapeuticsMD has a market cap of $20.95M. Its enterprise value, which adds debt and subtracts cash, is $10.50M.
How many shares of TXMD are outstanding?
TherapeuticsMD has 11.57M shares outstanding. The count is up 0.00% from a year earlier.
Does TXMD pay a dividend?
No. TherapeuticsMD does not pay a dividend.
How much debt does TXMD have?
TherapeuticsMD has $0 of total debt and $10.45M of cash and equivalents, a net cash position of $10.45M.
TXMD pages: Overview, Charting, Earnings, Financials, Statistics, Valuation, Competitors